T. Rowe Price Associates’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.43M | Buy |
281,667
+57,433
| +26% | +$291K | ﹤0.01% | 1807 |
|
|
2025
Q1 | $1.19M | Buy |
224,234
+92,244
| +70% | +$488K | ﹤0.01% | 1867 |
|
|
2024
Q4 | $893K | Buy |
131,990
+19,552
| +17% | +$132K | ﹤0.01% | 2013 |
|
|
2024
Q3 | $741K | Buy |
112,438
+24,323
| +28% | +$160K | ﹤0.01% | 2088 |
|
|
2024
Q2 | $661K | Buy |
88,115
+26,050
| +42% | +$195K | ﹤0.01% | 2070 |
|
|
2024
Q1 | $619K | Buy |
62,065
+5,501
| +10% | +$54.9K | ﹤0.01% | 2123 |
|
|
2023
Q4 | $558K | Buy |
56,564
+3,589
| +7% | +$35.4K | ﹤0.01% | 2128 |
|
|
2023
Q3 | $406K | Sell |
52,975
-23,851
| -31% | -$183K | ﹤0.01% | 2209 |
|
|
2023
Q2 | $574K | Buy |
76,826
+2,033
| +3% | +$15.2K | ﹤0.01% | 2054 |
|
|
2023
Q1 | $499K | Sell |
74,793
-1,126
| -1% | -$7.51K | ﹤0.01% | 2106 |
|
|
2022
Q4 | $585K | Buy |
75,919
+39,713
| +110% | +$306K | ﹤0.01% | 2060 |
|
|
2022
Q3 | $386K | Buy |
36,206
+13,406
| +59% | +$143K | ﹤0.01% | 2257 |
|
|
2022
Q2 | $186K | Sell |
22,800
-539,390
| -96% | -$4.4M | ﹤0.01% | 2618 |
|
|
2022
Q1 | $4.03M | Sell |
562,190
-295,383
| -34% | -$2.11M | ﹤0.01% | 1495 |
|
|
2021
Q4 | $14.7M | Buy |
857,573
+276,903
| +48% | +$4.74M | ﹤0.01% | 1342 |
|
|
2021
Q3 | $13.4M | Sell |
580,670
-2,415
| -0.4% | -$55.6K | ﹤0.01% | 1387 |
|
|
2021
Q2 | $21.3M | Buy |
+583,085
| New | +$21.3M | ﹤0.01% | 1288 |
|